Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05720767 · ClinicalTrials.gov registry record · Phase 1
HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study
A Phase 1 study, sponsored by Hutchmed.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT05720767 is a Phase 1 study that has completed, run by Hutchmed. The registered enrollment target is 28 participants.
The verdict
NCT05720767, a Phase 1 study, has completed, sponsored by Hutchmed.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
A Phase 1, Open-label, 2-Part, 2-Period Fixed-Sequence Crossover Study to Assess the Effect of Itraconazole, a CYP3A and P-glycoprotein Inhibitor, and the Effect of Rifampin, a CYP Enzyme Inducer, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers
Interventions
- DRUG Rifampin
- DRUG Itraconazole
- DRUG HMPL-523
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-11-04 |
| Est. Completion | 2023-02-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05720767
The ClinicalTrials.gov registry entry for NCT05720767 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hutchmed, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rifampin is the first listed.
NCT05720767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05720767 about?
NCT05720767 is a clinical study titled "HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study". A Phase 1, Open-label, 2-Part, 2-Period Fixed-Sequence Crossover Study to Assess the Effect of Itraconazole, a CYP3A and P-glycoprotein Inhibitor, and the Effect of Rifampin, a CYP Enzyme Inducer, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers
What is the current status of trial NCT05720767?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2022-11-04. Estimated completion is 2023-02-05.
What interventions are being tested in trial NCT05720767?
The interventions under investigation include: Rifampin (DRUG), Itraconazole (DRUG), HMPL-523 (DRUG).
Who is sponsoring clinical trial NCT05720767?
This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.